Exp Ther Med
-
In the clinical settings, patients often develop opioid-induced hyperalgesia (OIH) after utilization of high dose intra-operative remifentanil. Systemic α2 agonists, including dexmedetomidine, are believed to reduce pain and opioid requirements after surgery, thus decreasing the incidence of hyperalgesia. The present study aimed to investigate the effect of dexmedetomidine on remifentanil-induced hyperalgesia and explored the sex differences. ⋯ The present findings indicated that low- and high-dose dexmedetomidine injection significantly decreased the patient's risk of enhanced pain intensity and increased postoperative morphine dosing caused by remifentanil-induced hyperalgesia. These findings suggest that the influence of dexmedetomidine displayed minimal significant differences between sex. Trial registration no., IRB2018-YX-001 (Name of registry: Institutional Medical Ethics Committee of Tianjin Medical University General Hospital; date of registration: February 1, 2016).
-
Accumulating evidence suggests that microRNAs (miRs) exert vital functions in the development and progression of multiple types of human cancer. However, the role of miR-6852 in gastric cancer (GC) remains unclear. In the present study, miR-6852 expression was significantly downregulated in GC tissues compared with adjacent normal tissues determined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. ⋯ Rescue assays indicated that overexpression of FOXJ1 significantly reversed the effects of miR-6852 transfection on GC cell proliferation, migration and invasion. Taken together, the present findings demonstrated that miR-6852 exerted a tumor suppressive role through targeting FOXJ1 in GC. These results implied that miR-6852 may be a novel therapeutic target of GC treatment.